Inhibrx Biosciences, Inc. (INBX)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 1.3M | 0.00 | 0.00 | 0.00 |
| Operating Income | -27.4M | -33.8M | -30.9M | -30.9M |
| Net Income | -28.7M | -35.3M | -32.8M | -33.4M |
| Diluted EPS | $-1.85 | $-2.28 | $-2.11 | $-2.15 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.3M | 1.8M | 200K | 1.3M |
| Operating Income | -115.3M | -219.2M | -331.4M | -135.0M |
| Net Income | -115.3M | -241.4M | 1.7B | -140.1M |
| Diluted EPS | $-8.10 | $-16.95 | $112.62 | $-9.04 |